OMERS ADMINISTRATION Corp Takes Position in Moderna, Inc. $MRNA

OMERS ADMINISTRATION Corp acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,458 shares of the company’s stock, valued at approximately $942,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Assetmark Inc. boosted its holdings in Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock valued at $41,000 after acquiring an additional 208 shares during the last quarter. New Mexico Educational Retirement Board raised its holdings in Moderna by 1.9% during the 4th quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock worth $463,000 after purchasing an additional 300 shares during the last quarter. IFP Advisors Inc lifted its position in shares of Moderna by 5.4% in the 4th quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock worth $200,000 after purchasing an additional 348 shares during the period. Empowered Funds LLC boosted its stake in shares of Moderna by 2.6% in the 4th quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock valued at $405,000 after purchasing an additional 353 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators increased its position in shares of Moderna by 16.9% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,640 shares of the company’s stock worth $78,000 after buying an additional 382 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. This represents a 4.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.80% of the company’s stock.

Moderna Stock Performance

NASDAQ MRNA opened at $142.77 on Friday. The company has a market cap of $57.00 billion, a P/E ratio of -17.87 and a beta of 0.91. The company has a fifty day simple moving average of $75.62 and a 200 day simple moving average of $59.17. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $176.66.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. The business’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.13) earnings per share. Sell-side analysts predict that Moderna, Inc. will post -6.18 earnings per share for the current fiscal year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: The FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, which target the XFG subvariant. The approval supports Moderna’s ability to participate in the upcoming seasonal vaccination market, although Spikevax eligibility is focused on adults 65 and older and higher-risk people ages 6 months through 64. FDA approves updated COVID vaccines
• Positive Sentiment: Renewed attention on Moderna and Merck’s personalized cancer vaccine, intismeran, is supporting the company’s long-term oncology story. Reports indicate the therapy reduced melanoma recurrence by approximately 49% in a late-stage study, strengthening expectations that Moderna could diversify beyond its declining COVID-19 business. Personalized melanoma vaccine results
• Neutral Sentiment: Moderna announced plans to raise $2 billion through convertible senior notes due in 2032, with an option for purchasers to increase the deal to $2.3 billion. Proceeds may fund oncology investments and debt repayment, while a hedge overlay is intended to offset dilution up to a specified cap. Moderna convertible notes offering
• Negative Sentiment: Investors are reacting cautiously to the financing because convertible notes can create future share dilution and signal substantial funding needs. The offering comes while Moderna remains unprofitable, making the company’s elevated valuation more difficult to justify on current earnings and revenue. Moderna borrows $2 billion

Analyst Upgrades and Downgrades

A number of analysts have commented on MRNA shares. JPMorgan Chase & Co. upped their price target on shares of Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. The Goldman Sachs Group lifted their target price on Moderna from $67.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, August 19th. Loop Capital set a $135.00 price target on Moderna in a report on Wednesday, August 19th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $130.00 target price on shares of Moderna in a research report on Wednesday, August 19th. Finally, Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a report on Tuesday. Four research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Moderna presently has an average rating of “Hold” and a consensus target price of $74.31.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.